University of Michigan Rogel Cancer Center

University of Michigan Rogel Cancer Center Our mission is the conquest of cancer through innovation and collaboration.
(774)

Kyle Kipke had a history of prostate cancer in his family, which prompted him to get regular checkups. In February 2022,...
03/30/2026

Kyle Kipke had a history of prostate cancer in his family, which prompted him to get regular checkups. In February 2022, he had a colonoscopy that revealed a re**al tumor.

His UM care team laid out a treatment plan that included chemotherapy and radiation. Eight months later, Kipke completed his treatment.

Learn more about his journey at https://michmed.org/7KWM9.

When a person with cancer finds out they carry an inherited genetic variant that puts them at higher risk of cancer, the...
03/27/2026

When a person with cancer finds out they carry an inherited genetic variant that puts them at higher risk of cancer, the results can help inform their treatment or steps to prevent additional cancer.

But what about their family members who may also have inherited that genetic variant?

“Few medical tests have implications for others beyond the patient. But with germline genetic testing, the results can be very significant to the health of others around you,” said Steven J. Katz, M.D., M.P.H., a researcher at the University of Michigan Health Rogel Cancer Center.

Katz and colleagues developed a web-based intervention to educate people with cancer about the impact genetic variants can have on their family. The platform also allows patients to invite first- and second-degree relatives to the site, where they get information about genetic risk and access to testing. https://michmed.org/4kY2n

The best approach to treating pancreatic cancer involves knowing Plan A, Plan B and Plan C right from the beginning."Bec...
03/20/2026

The best approach to treating pancreatic cancer involves knowing Plan A, Plan B and Plan C right from the beginning.

"Because pancreatic cancer is so challenging, it’s crucial to deliver the best possible treatment for the patient as early in their diagnosis as possible," says Dr. Evan Glazer, a surgeon at the Rogel and Blondy Center for Pancreatic Cancer.

Do your research and find the best treatment center right from the start. Dr. Glazer shares what to look for. https://michmed.org/bQ2yK

03/20/2026

At age 31, Andrew Sweeney was diagnosed with stage 4 colore**al cancer with metastases in his liver.

After initial surgery and chemotherapy, Sweeney and his U-M care team made history.

Learn how Sweeney became first patient in Michigan to receive a liver transplant as part of treatment for colon cancer: https://michmed.org/vQnqz.

We are fighting to preserve access to our care for patients like these. Learn more: uofmhealth.org/BCBSM.

Today is ! It’s time to change lives and shape the future with Michigan Medicine. See how your gift can impact people w...
03/18/2026

Today is ! It’s time to change lives and shape the future with Michigan Medicine. See how your gift can impact people with cancer and their families.

Please consider giving to one of our special programs: Bone Marrow Transplant Program or the Radiation Oncology Resident Research Program. Gifts of every size make a difference! https://victors.us/gbdmimed26

At age 31, Andrew Sweeney was diagnosed with stage 4 colore**al cancer with metastases in his liver. He underwent surger...
03/16/2026

At age 31, Andrew Sweeney was diagnosed with stage 4 colore**al cancer with metastases in his liver.

He underwent surgery to remove the mass in his colon and received chemotherapy for one and a half years to shrink the tumors in his liver.

Sweeney and his U-M care team then made history.

Learn how Sweeney became first patient in Michigan to receive a liver transplant as part of treatment for colon cancer: https://michmed.org/vQnqz.

For years, colore**al cancer prevention has been one of medicine’s success stories. Widespread screening has led to majo...
03/11/2026

For years, colore**al cancer prevention has been one of medicine’s success stories. Widespread screening has led to major drops in both diagnoses and deaths among adults age 50 and older.

However, Dr. Elena Stoffel warns that colore**al cancer is rising fast in younger adults—and our health care system hasn’t fully caught up yet.

Find out what steps clinicians are taking to address this emerging challenge at https://michmed.org/kVZNk.

Colore**al cancer is the third most common cancer in the United States. Although screening has led to a decrease in inci...
03/06/2026

Colore**al cancer is the third most common cancer in the United States. Although screening has led to a decrease in incidence over the past 20 years, early-onset colore**al cancer has been rising.

In patients with colore**al cancer, the protein STAT3 is continuously activated, leading to tumor growth.

In a new study, U-M researchers have shown that glucose levels sustain increased STAT3 activation in colore**al cancer cells.

Learn more about how targeting glucose metabolism could lead to novel therapeutic strategies: https://michmed.org/DQ2rM.

Josephine “JoJo” Wells was born as a spontaneous triplet—a rare occurrence that happens in 1 out of one million pregnanc...
02/27/2026

Josephine “JoJo” Wells was born as a spontaneous triplet—a rare occurrence that happens in 1 out of one million pregnancies.

When she was nine months old, JoJo was diagnosed with hepatoblastoma, a rare liver cancer affecting one in a million children in the United States.

After six cycles of chemotherapy and a surgery to remove the tumor, JoJo continues to be in remission.

As we recognize Rare Disease Day tomorrow, read about JoJo's treatment journey: https://michmed.org/YWV8w.

02/26/2026

Treating cancer is a team effort. Liver cancer is no exception. Through team discussions and patient evaluations, those with certain liver tumors have access to latest treatment options.

Gastroenterologist Neehar Parikh along with interventional radiologist Mishal Mendiratta-Lala discuss the latest treatment option for liver cancer – Histotripsy.

Histotripsy was created at the University of Michigan and has been approved by the FDA for use on liver tumors. While still relatively new, the dedicated clinic for patients who could benefit from Histotripsy, offers them a non-invasive approach with very good outcomes in order maintain their quality of life.

Liposarcoma is the most common type of soft tissue sarcoma, accounting for 15-20% of the diagnoses. There has been littl...
02/26/2026

Liposarcoma is the most common type of soft tissue sarcoma, accounting for 15-20% of the diagnoses.

There has been little progress in understanding and treating liposarcoma due to its rarity and lack of research resources.

In a new study, U-M researchers have developed a mouse model that mirrors the disease in humans.

Learn from Dr. Angeles how the new mouse model can help researchers develop novel therapies: https://michmed.org/Q9VJA.

You've had a cancer screening test and there was an anomaly. You then get a biopsy. So how does that determine if you ha...
02/25/2026

You've had a cancer screening test and there was an anomaly. You then get a biopsy. So how does that determine if you have cancer? Pathologist Dr. Cathryn Lapedis, shares pathology's role in cancer determination and in the patients care in the latest Caner Aware podcast. 👂https://michmed.org/NYVQk

Address

1500 E Medical Center Drive
Ann Arbor, MI
48109

Telephone

+18008651125

Website

Alerts

Be the first to know and let us send you an email when University of Michigan Rogel Cancer Center posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category